Recent advances in nanomaterial-based synergistic combination cancer immunotherapy
In recent years, conventional treatments including surgery, chemotherapy and radiotherapy have been the main approaches in tumour therapy. Cancer immunotherapy is a new therapeutic modality to fight cancer by harnessing the power of patients' own immune system. Ongoing research related to these...
Saved in:
| Published in | Chemical Society reviews Vol. 48; no. 14; pp. 3771 - 381 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Royal Society of Chemistry
15.07.2019
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Summary: | In recent years, conventional treatments including surgery, chemotherapy and radiotherapy have been the main approaches in tumour therapy. Cancer immunotherapy is a new therapeutic modality to fight cancer by harnessing the power of patients' own immune system. Ongoing research related to these therapies has demonstrated their advantages and intrinsic limitations. Nanomaterial-based platforms are utilized in these emerging fields. In particular, a combination of other treatment methods with cancer immunotherapy to achieve precision medicine and prevent recurrence and metastasis, could improve patients' outcome. The combined multiple treatments have superior efficacy to any monotherapy alone in producing improved anti-cancer activity. Therefore, it's necessary to summarise research advances in nanomaterial-based combination cancer immunotherapy contributing to clinical transformation. This review is based on the principles of cancer immunotherapy and the combined treatment design reflected by advances in materials science, including the structures of nanoplatforms and their underlying mechanisms towards cancer. The ultimate goals are to stimulate the design of better strategies for versatile use in the future based on biomaterial engineering methods to enhance the efficacy of combined cancer treatments, and to provide new ideas for the prospects of a synergistic cancer combination immunotherapy for clinical application transformation.
This review aims to summarize various synergistic combination cancer immunotherapy strategies based on nanomaterials. |
|---|---|
| Bibliography: | Dr Yunlu Dai is an assistant professor in the Faculty of Health Sciences, University of Macau. He received his PhD degree in 2014 from the Changchun Institute of Applied Chemistry (CIAC), Chinese Academy of Sciences, under the supervision of Prof. Jun Lin. Then he moved to the University of Melbourne as a research fellow with Prof. Frank Caruso. In 2016, he joined Dr Xiaoyuan (Shawn) Chen's Laboratory in the National Institutes of Health (NIH) as a postdoctoral fellow. He initiated his independent research program in 2018 at the University of Macau. His research focuses on multifunctional hybrid nanomaterials for cancer theranostics. diagnostics index = 128, total citations >59 000 based on Google Scholar) and numerous books and book chapters. He is the founding editor of the journal in vitro Wei Sang received her BSc degree from Guangdong Pharmaceutical University in 2015. Then she studied in the Institute of Chinese Medical Sciences/State Key Laboratory of Quality Research in Chinese Medicine in the University of Macau, China, and received her Master of Science degree. She then joined as a PhD student in the research group of Dr Yunlu Dai in the Faculty of Health Sciences, University of Macau, China, in 2018. Her research interests include nanomaterials for cancer immunotherapy and biological imaging. Zhan Zhang, as a seven-year program student, received his MD degree (2018) in surgery from Dalian Medical University, under the supervision of Prof. Liming Wang. He is currently a PhD student with Dr Yunlu Dai in the Faculty of Health Sciences at the University of Macau. His research interests mainly focus on modifying metal-organic frameworks and metal-phenolic nanoparticles for drug delivery, bioimaging and cancer therapy. Dr Xiaoyuan (Shawn) Chen is a Senior Investigator and Chief of the Laboratory of Molecular Imaging and Nanomedicine (LOMIN) at the National Institute of Biomedical Imaging and Bioengineering (NIBIB), NIH. His current research interests include H in vivo molecular imaging and molecular therapeutics, including nanotheranostics. Dr Chen has published over 750 peer-reviewed papers (2017 IF = 8.537). Theranostics ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| ISSN: | 0306-0012 1460-4744 1460-4744 |
| DOI: | 10.1039/c8cs00896e |